Sphera Funds Management Ltd. Krystal Biotech, Inc. Transaction History

Sphera Funds Management Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $1.24 Million - $1.86 Million	-25,310 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $1.32 Million - $1.83 Million	25,310 New	25,310 $1.68 Million
Q1 2021 May 17, 2021	SELL	$59.42 - $85.46 $6 Million - $8.64 Million	-101,044 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $3.39 Million - $5.13 Million	-83,529 Reduced 45.26%	101,044 $6.06 Million
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $1.51 Million - $1.94 Million	40,000 Added 27.67%	184,573 $7.95 Million
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $5.35 Million - $8.67 Million	144,573 New	144,573 $5.99 Million
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $3.02 Million - $5.66 Million	-86,280 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$33.17 - $65.23 $1.04 Million - $2.04 Million	-31,345 Reduced 26.65%	86,280 $4.78 Million
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $1.74 Million - $2.64 Million	-64,000 Reduced 35.24%	117,625 $0
Q1 2019 May 15, 2019	BUY	$19.86 - $32.9 $139,020 - $230,300	7,000 Added 4.01%	181,625 $5.98 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $2.62 Million - $4.43 Million	174,625 New	174,625 $3.63 Million

310

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.23B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.